Chemical Treatment for Osteoporosis

 

Executive Summary

 

In the United States alone, 10 million people are afflicted, and 18 million more are at risk of developing the bone disease, osteoporosis. The large market for osteoporosis treatments and the fact that currently available therapeutics have the potential to produce severe negative side effects or are required to be administered via injection. This demonstrates the need for new therapeutics that overcome these challenges.

 

Description of Technology

 

This technology uses high molecular weight polyethylene glycol (HMW-PEG) to treat osteoporosis. HMW-PEG has been previously shown to enhance GI mucinous and cytoskeletal barriers that prevent pathogenic gut bacteria from interacting with or invading the gut wall at points of weakness leading to systemic inflammation. Inflammation  has been linked to bone loss leading to osteoporosis. Here, the inventor has demonstrated that HMW-PEG has positive effects on bone formation in mice.

 

Key Benefits

  • Minimal side effects
  • Easy delivery—orally taken
  • Promotes bone formation 

 

Applications

  • Osteoporosis treatment
  • Bone degeneration conditions

 

Patent Status:

 

PCT/US2014/028832

 

Licensing Rights Available

 

Non-exclusive rights

 

Inventors: Laura McCabe, Rifat Pamukcu

 

Tech ID: TEC2013-0086

 

Alternative contact due to temporary leave:

 

Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829. 

 

Patent Information:

For Information, Contact:

Randy Ramharack
Technology Manager
Michigan State University
ramharac@msu.edu
Keywords: